Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Maine for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Maine only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Maine (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Can Ilyas (NPI 1770625410)

Field	Value
Entity Type	Individual
Organization	Can Ilyas
Address	2 Independence Dr
City	Kennebunk
State	ME
ZIP	04043
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	February 12, 2007

Payer Source	Total Paid
Medicare	$3.2M
Medicaid	$0

Key Findings

This provider is effectively single‑payer in scope for the data on file: Total Medicare revenue is $3.2M and there is no Medicaid billing on file, indicating the practice’s Medicare activity is the primary driver of reported throughput and revenue. The absence of Medicaid claims suggests limited or no engagement with state Medicaid populations in the reported period, concentrating commercial/political reimbursement exposure on Medicare policy and pricing for high-cost oncology drugs.

Revenue is highly concentrated in a small set of oncology drug codes: the precomputed top three Medicare codes account for 79.8% of the provider's Medicare revenue. Those top three are J9271 ($1.4M, 43.3%), J9299 ($862.6K, 27.1%), and J0897 ($298.9K, 9.4%), which together create substantial dependence on a few high-cost biologic therapies for the practice’s revenue stream.

The code mix and service-level codes indicate an infusion-centric hematology/oncology operation: dominant use of J9271 (pembrolizumab) and J9299 (nivolumab) together with multiple infusion and chemotherapy administration codes (96413, 96365, 96375, 96401, 96417) points to onsite administration of immune checkpoint inhibitors and parenteral cancer therapies. Routine lab codes (80053, 85025, 82728, 84443) and frequent basic venipuncture (36415) further support an integrated clinic model that combines infusion, laboratory monitoring, and E/M visits.

The provider shows above-typical national standing on several high-revenue oncology drugs: J9271 is described as notably above typical national volume and ranks #102 of 1841 providers (94th percentile), and J0897 also ranks highly as notably above typical volume (#379 of 10057, 96th percentile). By contrast, J9299, while generating $862.6K and ranking #44 of 505 providers, is characterized in the dataset as a typical, unremarkable volume for that code—this mix suggests the provider is a major national participant for some agents but not uniformly dominant across all PD‑1/PD‑L1 therapies.

Office evaluation-and-management billing is an outlier relative to national peers: 99214 produced $145.7K from 1.6K claims (4.6% of Medicare revenue) and is labeled an extreme outlier, ranking in the 99th percentile. This pattern suggests elevated established-patient visit volume or higher-intensity E/M coding that accompanies an active outpatient oncology practice and frequent follow-up visits for patients receiving infusion therapies.

There are operational scale signals in very high claim counts for low-dollar items: J1439 shows 98.3K claims and $98.3K revenue (3.1% of Medicare revenue) and is labeled notably above typical national volume, indicating a high-frequency service (ferric carboxymaltose infusions) within the practice. Along with numerous administration and infusion codes (e.g., 96375 with 714 claims), this reinforces the interpretation of a clinic optimized for repeated in-office infusions and ancillary services rather than one dominated by only episodic visits.

Payer and portfolio concentration creates potential commercial sensitivity: with $3.2M in Medicare revenue and no Medicaid billing, the practice’s topline is concentrated in Medicare reimbursement for expensive biologic agents (notably pembrolizumab and nivolumab). Any shifts in Medicare pricing, reimbursement policy for these agents, or utilization management could materially affect revenue because the top three codes account for 79.8% of Medicare revenue.

The provider has an established tenure and persistent presence: NPI was enumerated on 2007-02-12 (~19 years ago), indicating long-term activity in the market. Coupled with multiple top-percentile rankings on high-revenue oncology drugs, this tenure suggests an experienced, stable practice that has scaled infusion and supportive-care services over time.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

66 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	32,000	$40	$1.4M
J9299	Injection, nivolumab, 1 mg	35,940	$20	$862.6K
J0897	Injection, denosumab, 1 mg	17,580	$20	$298.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,550	$90	$145.7K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	3,050	$40	$109.8K
J1439	Injection, ferric carboxymaltose, 1 mg	98,250	$1	$98.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	710	$100	$72.6K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	220	$130	$29.9K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	80	$340	$27.5K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	180	$140	$24.4K

Showing 1–10 of 66

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 66 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Maine Distribution

Can Ilyas — 15 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Maine

Full comparison — all codes billed, vs. state median

66 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	10	16,450	$40	$699.2K
J9299	1	10	30,720	$20	$671.3K
J1569	4	10	3,150	$40	$144.9K
J0897	1	20	2,730	$20	$86.4K
J0881	7	10	15,200	$1	$47K
J1439	1	10	24,750	$1	$32.2K
J9217	2	10	120	$130	$27.9K
96413	1	30	170	$100	$20.6K
J1454	1	10	60	$340	$18.3K
91322	129	140	60	$140	$13.3K

Showing 1–10 of 66

Related Providers

Other providers that share a Tax Identification Number (TIN) with Can Ilyas, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mercy Hospital	ME	General Acute Care Hospital	$0	$35.5M
David Benton	ME	Hematology & Oncology Physician	$2.6M	$0
Matthew Dugan	ME	Hematology & Oncology Physician	$1.8M	$0
John Winters	ME	Hematology & Oncology Physician	$1.5M	$0
Maine Center For Cancer Medicine & Blood Disorders, P.A.	ME	Hematology & Oncology Physician	$0	$1.5M
Christian Thomas	ME	Hematology & Oncology Physician	$1.5M	$0
Devon Evans	ME	Hematology & Oncology Physician	$1.5M	$0
Brian Haney	ME	Hematology & Oncology Physician	$1.2M	$0
Yoko Fukuda	NH	Hematology & Oncology Physician	$945K	$0
Jonathan Proulx	NH	Hematology (Internal Medicine) Physician	$725.4K	$0

Nearby Providers

Other providers in the same ZIP code as Can Ilyas, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
React Behavioral Health, LLC	ME	Community/Behavioral Health Agency	$0	$6.5M
Kennebunk Operations, LLC	ME	Skilled Nursing Facility	$0	$3.8M
Kennebunk Walk-in Clinic	ME	Family Medicine Physician	$0	$1.1M
Acorn & Oak LLC	ME	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$1.1M
York County Pediatric Dentistry	ME	Dental Clinic/Center	$0	$814.3K
Town Of Kennebunk	ME	Land Ambulance	$321.7K	$415.5K
Cvs State Capital, L.L.C.	ME	Pharmacy	$225.4K	$0
Brian Ewy	ME	Diagnostic Radiology Physician	$151.6K	$7.5K
Nina Shervin	ME	Orthopaedic Surgery Physician	$153.3K	$0
Kenneth Warren	ME	Foot & Ankle Surgery Podiatrist	$126.5K	$0

Can Ilyas — Billing Profile & Reimbursement Data

Sign up for Can Ilyas — Billing Profile & Reimbursement Data policy alerts

Can Ilyas — Billing Profile & Reimbursement Data

Sign up for Can Ilyas — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References